Meta Information

ID:retatrutide

Name:Retatrutide

Schema Version:1.5

Title

Retatrutide

Alternate Names

• LY3437943

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

0

High Cost:

0

Cost Type:

monthly

Description:

Not commercially available; cost is unknown as it is in clinical trials.

Summary

Retatrutide is an investigational triple agonist for the GIP, GLP-1, and glucagon receptors, a mechanism that combines appetite suppression with increased energy expenditure. This multi-pathway approach has demonstrated unprecedented levels of weight loss and improvement in metabolic markers like insulin sensitivity and liver fat in clinical trials. Its healthspan relevance lies in its potential to powerfully reverse metabolic syndrome, a key accelerator of multiple age-related diseases.

Purpose

Triple-agonist peptide for profound weight loss and metabolic health improvement.

Card Summary

An investigational triple-agonist (GIP/GLP-1/glucagon) peptide showing unprecedented weight loss and metabolic benefits in clinical trials.

Drug Class

glp-1-receptor-agonists

Drugs In Class

Empty Array

Impact

Score:

8.5

Justification:

Potentially foundational impact on metabolic health, a core driver of aging.

Evidence

Grade:

B

Score:

7.5

Justification:

Strong Phase 2 human RCT data, but long-term outcomes are not yet established.

Safety

Score:

6.1

Justification:

Experimental drug with common GI side effects; requires intensive medical supervision.

Flags

• Currently an investigational drug and not approved for public use.
• Common side effects include nausea, diarrhea, and vomiting, especially during dose escalation.
• Potential for interactions with other medications affecting gastric emptying or blood sugar.
• Long-term safety profile beyond clinical trial duration is unknown.

Verdict

A potentially game-changing metabolic intervention, pending final trial data and approval.

Created

2026-04-24T00:08:16.188310Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

subcutaneous_injection

Scope:

• systemic

Indication

Focus:

healthspan

Description:

Retatrutide is an investigational triple agonist for the GIP, GLP-1, and glucagon receptors, a mechanism that combines appetite suppression with increased energy expenditure. This multi-pathway approa...

Typical Protocol

• Currently investigational; clinical trials are evaluating weekly subcutaneous injections from 1 mg to 12 mg.